Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland by Cantwell, M M et al.
Short Communication
Second primary cancers in patients with skin cancer:
a population-based study in Northern Ireland











1Cancer Epidemiology and Prevention Research Group, Centre for Clinical and Population Sciences, Queen’s University Belfast, Belfast, Northern Ireland;
2Queen’s University Belfast, Northern Ireland Cancer Registry, Royal Victoria Hospital, Belfast, Northern Ireland;
3Epidemiology Methods and Support
group, International Agency for Research on Cancer, Lyon, France;
4Department of Dermatology, Royal Victoria Hospital, Belfast, Northern Ireland
Among all 14500 incident cases of basal cell carcinoma (BCC), 6405 squamous cell carcinomas (SCC) and 1839 melanomas
reported to the Northern Ireland Cancer Registry between 1993 and 2002, compared with the general population, risk of new
primaries after BCC or SCC was increased by 9 and 57%, respectively. The subsequent risk of cancer, overall, was more than double
after melanoma.
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Melanoma and non-melanoma skin cancers (NMSC) (basal cell
carcinoma (BCC) and squamous cell cancer (SCC)) show an
increasing incidence worldwide (Jemal et al, 2001), including
Northern Ireland (Hoey et al, 2007). There are limited epidemio-
logical data concerning whether individuals with skin cancer are at
an elevated risk of developing other malignancies. Tuohimaa et al
(2007) combined data from 13 cancer registries and found 23 and
39% increased risks of several second primary cancers after a
melanoma or NMSC, respectively. Decreases in risk of prostate
(De Vries et al, 2007) and colorectal cancer (Soerjomataram et al,
2008) have been reported following a skin cancer, whereas a recent
meta-analysis showed a significant reduction in colon cancer
among patients with previous SCC (Grant, 2007).
We investigated the subsequent risk for any cancer in patients
with BCC, SCC or melanoma. We also examined the reciprocal
association for subsequent skin cancer after a primary colorectal
cancer (as a validation exercise), as we hypothesised that patients
with colorectal cancer, a cancer related to low vitamin D levels
(Gorham et al, 2007), would have had a lower lifetime exposure to
the sun and therefore have a lower risk of a subsequent skin
cancer.
MATERIALS AND METHODS
The Northern Ireland Cancer Registry (NICR) is a population-
based registry that receives data routinely from 13 hospital
administration systems, five pathology laboratories and eight
radiology sites. It holds complete data on all neoplasms diagnosed
within the province since the beginning of 1993. In addition,
a partially complete database of tumours diagnosed between 1989
and 1992 is also held by the NICR. Patients with pathologically
confirmed NMSC are registered according to the European
Network of Cancer Registries’ guidelines for NMSC (Davies et al,
2007), which recommend that only the first occurrence of NMSC is
registered based upon date of diagnosis and histological type (BCC
or SCC). The latter is quality assured by NICR using all available
information (such as primary site, patient history and general
knowledge of tumour biology). Version 10 of the International
Classification of Diseases was used to identify NICR registrations
of NMSC (C44) and malignant melanoma (C43). Non-melanoma
skin cancer cases registered with SNOMED codes between 80903
and 80953 were considered as BCC whereas those with SNOMED
code 80703 or 80713 were considered SCC. Other types of NMSC
were excluded from the analysis (1183 patients) due to the variety
of histological types in the small number of patients.
In addition, the 1989–1992 database was used to eliminate from
the 1993–2002 cohorts patients diagnosed with NMSC or
melanoma during 1989–1992. A further 58 BCC, four SCC and
two melanoma patients were also excluded as they were either
diagnosed outside Northern Ireland (and could therefore not be
followed for subsequent cancer risk) or were 100 years old or more
when diagnosed. In total, 1837 melanoma, 6401 SCC and 14442
BCC patients were followed up to 31 December 2002 for a second
primary neoplasm or death, the latter through linkage to death
records held by the Registrar General’s Office (GRO), Northern
Ireland.
The outcome measures were classified according to ICD 10 as
follows:
Any malignant neoplasm C00–C97; melanoma C43; SCC C44;
BCC C44; lung C33 and C34; breast (female only) C50; cervix C53;
uterus C54; ovary C56; prostate C61; oesophagus and stomach C15
and C16; colorectal C18–C21; haematological malignancies
C81–C96; and non-Hodgkin’s lymphoma C82–C85. Tobacco-
related cancers were also grouped as one outcome variable
and included ICD 10 codes C00–C16, C22, C25, C32–34, C53,
C64–C68 and C92.
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Observed numbers of cancers and person-years at risk were
calculated by sex and 5-year age group. Expected numbers of
cancers were obtained by multiplying the age-specific numbers of
person-years with the corresponding cancer incidence rates in
Northern Ireland, adjusting for gender for the overall standardised
incidence ratios (SIRs). Exact 95% confidence intervals (CIs) were
calculated, assuming that the numbers of observed cases followed a
Poisson distribution (Breslow and Day, 1987).
RESULTS
The absolute incidence of BCC was 86.6 cases per 100000 person-
years and the mean (s.d.) age at diagnosis was 66.7 (s.d. 12.9) years
in men and 69.0 (s.d. 13.9) in women. Compared with the general
population, overall, the BCC patients had a 9% increased incidence
of new primary cancers, more than a two-fold increased risk of
subsequent melanoma and 14% increased risk of SCC (Table 1).
The absolute incidence of SCC was 38.4 cases per 100000
person-years and the mean (s.d.) age at diagnosis was 72.4 (11.4)
years in men and 76.1 (12.0) years in women. In SCC patients, new
primaries at any site were increased by more than 50% and the
BCC incidence by more than two-fold (Table 2). Melanoma
incidence was three times higher in men but not higher in women
with an SCC and subsequent tobacco-related cancers were more
likely in both sexes. Women with an SCC were less likely to have a
subsequent breast cancer.
The absolute incidence of melanoma was 11.0 cases per 100000
person-years. The mean (s.d.) age at diagnosis was 56.6 (18.3)
years in men and 55.4 (20.3) years in women. Melanoma was
followed by an increased risk of any subsequent cancer
(SIR¼2.06; 95% CI 1.73–2.39), melanoma (SIR¼4.79; 95% CI
1.24–8.34), BCC (SIR¼4.95; 95% CI 3.78–6.12) and SCC
(SIR¼2.50; 95% CI 1.24–3.77).
During the study period, the 9144 individuals registered with
colorectal cancer showed, in contrast to our hypothesis, an
increased risk of a second cancer (SIR¼1.31; 95% CI 1.20–1.42)
and an increased risk of BCC (SIR¼1.36; 95% CI 1.11–1.61), a
sun-related cancer. In addition, their subsequent risk of develop-
ing other cancers related to low vitamin D levels, such as prostate
and breast cancer, was not increased (SIR¼0.97; 95% CI 0.66–1.28
and SIR¼0.89; 95% CI 0.55–1.23, respectively).
DISCUSSION
Our population-based study included all incident cases of BCC
(14422), SCC (6401) and melanoma (1837) reported to the
Northern Ireland Cancer Registry between 1993 and 2002.
Compared with the general population, the incidence of new
primaries after BCC or SCC was increased by 9 and 57%,
respectively. However, the subsequent risk of any cancer was
more than double after melanoma.
Using NMSC, as a surrogate measure of long-term sun exposure,
has suggested that exposure is associated with a lower risk of
prostate cancer (de Vries et al, 2007). Our findings do not agree,
and men with a BCC, SCC or melanoma did not have a decreased
prostate cancer risk. An appreciable body of evidence suggests that
the beneficial effect of continuous sun exposure on colorectal
cancer risk is mediated through effects on the metabolism of
vitamin D, as this can suppress cell proliferation, cancer
development and metastasis (Gorham et al, 2007). We therefore
hypothesised that colorectal cancer would be associated with a
lower risk of other sun-related cancers (skin cancer) and a higher
risk of developing cancers related to low vitamin D levels.
In contrast, we found that they had an increased risk of a
subsequent BCC and that their subsequent risk of prostate and
breast cancer was not increased. Our results agree with those of
Tuohimaa et al (2007), who reported that NMSC is only protective
against subsequent solid cancers in sunny countries, which
perhaps indicates a less variable vitamin D exposure and in turn
less variable vitamin D status than in Northern, less sunny
countries. In such countries, as Northern Ireland, vitamin D
production from solar UVB is lower due to both shorter vitamin D
production seasons and lower peak UVB doses (Grant, 2008).
Table 1 New cancer in 14442 patients with basal cell carcinoma of the skin in Northern Ireland: 1993–2002 (all ages)
Cancer in men Cancer in women Cancer in men and women
Site ICD 10 n SIR (95% CI) n SIR (95% CI) n SIR (95% CI)
All C00–C97 674 1.11 (1.03, 1.19)* 530 1.07 (0.98, 1.17) 1204 1.09 (1.03, 1.16)*
All excluding
non-melanoma skin cancer
C00–C97 ex C44 460 1.01 (0.92, 1.10) 391 1.08 (0.97, 1.19) 851 1.04 (0.97, 1.11)
Skin, melanoma C43 19 2.68 (1.47, 3.88)* 19 2.11 (1.16, 3.07)* 38 2.36 (1.61, 3.11)*
Skin, squamous cell C44 214 1.27 (1.10, 1.44)* 139 0.99 (0.83, 1.15) 353 1.14 (1.02, 1.26)*
Lung C33, C34 101 1.13 (0.91, 1.36) 51 1.19 (0.86, 1.51) 152 1.15 (0.97, 1.33)
Breast (female only) C50 83 1.02 (0.80, 1.24)
Cervix C53 1
Uterus C54 19 1.52 (0.84, 2.21)
Ovary C56 10 0.61 (0.23, 1.00)
Prostate C61 107 1.17 (0.95, 1.39)
Oesophagus and stomach C15, C16 34 0.90 (0.60, 1.20) 24 1.04 (0.62, 1.46) 58 0.95 (0.71, 1.20)
Oesophagus C15 12 0.91 (0.40, 1.43) 6 0.69 (0.14, 1.23) 18 0.82 (0.44, 1.20)
Stomach C16 22 0.90 (0.52, 1.27) 18 1.26 (0.68, 1.84) 40 1.03 (0.71, 1.35)
Colorectal C18–C21 67 0.90 (0.68, 1.11) 65 1.10 (0.83, 1.37) 132 0.99 (0.82, 1.16)
Colon C18 44 0.92 (0.65, 1.19) 41 0.99 (0.69, 1.30) 85 0.95 (0.75, 1.15)
Rectum C19–C21 23 0.85 (0.50, 1.20) 24 1.34 (0.80, 1.87) 47 1.05 (0.75, 1.35)
Haematological malignancies C81–C96 45 1.24 (0.88, 1.60) 29 1.01 (0.64, 1.38) 74 1.14 (0.88, 1.40)
Non-Hodgkin’s lymphoma C82–C85 19 1.30 (0.72, 1.89) 17 1.20 (0.63, 1.77) 36 1.25 (0.84, 1.66)
Tobacco-related cancers C00–C14, C15, C16, C22,
C25, C32, C33, C34, C53,
C64–C66, C67, C68, C92
193 0.95 (0.81, 1.08) 113 1.02 (0.83, 1.21) 306 0.97 (0.86, 1.08)
CI¼confidence interval; SIR¼standardised incidence ratio. Bold values indicate *Po0.05.
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yWe found that SCC patients were at a high risk of subsequent
melanoma, confirming the results of Wassberg et al (1999), who
reported an almost three-fold increase in melanoma risk. This is
most likely due to a shared phenotype and environmental risk
factors, although patients with NMSC are more likely to be
screened for melanoma, and thereby have a spuriously high
melanoma rate.
Subsequent tobacco-related cancers were more likely in SCC
patients and this is not a surprising finding as cigarette smoking
has been associated with a two-fold increased risk of SCC
(Grodstein et al, 1995).
In general, an association between skin cancer and a second
primary cancer could reflect shared aetiologic factors or biased
ascertainment of new primaries as a result of increased surveillance
(Schottenberg 1996). It should also be noted that individuals who are
at a high risk of skin cancer may have other risk-taking behaviours
related to their increase in risk of a second primary cancer such as
smoking, dietary intake and physical activity levels.
There are some limitations to our study. Although based on the
past 10 years data, the mean period of follow-up was only 4 years
primarily due to the advanced age of patients at diagnosis,
especially within the SCC cohort. Our study concerns
a predominantly white population and so is not generalisable to
other racial, ethnic groups. A general limitation to this and other
registry-based investigations is the lack of information about
individual UV exposures and other hypothesised risk factors
Several strengths of our study include the availability of data by
NMSC subtype and its inclusion of data on all pathologically
confirmed NMSC in Northern Ireland. Loss to follow-up is likely to
be low; data from the GRO (Northern Ireland) estimate that less
than 0.1% of the population migrated from the province per year
during the 1990s (NISRA, 2008). Population-based studies of BCC
are rare as hospitalisation is not required, prognosis is favourable
and it is not routinely registered in most cancer registries.
Our results show that patients with a BCC, SCC or melanoma,
compared with the general population, have an increased risk of
developing a new primary cancer, especially melanoma in men.
Our findings may partly reflect risk factors in common between
these tumours, such as UV exposure and smoking, but they do not
agree with some earlier reports of a decreased risk of prostate
cancer after skin cancer perhaps mediated through vitamin D
production.
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